Key result
Propafenone is associated with arrhythmia control in ~60% of newborns and young children.
Population
65 children aged 0-5 years with arrhythmias including 16 with congenital heart defects
Comparison
Propafenone therapy with dose titration to effectiveness
Design
Observational study with ECG, Holter monitoring, and echocardiography
Authors
Loading...
May warrant consideration for pediatric arrhythmias; leaves open need for randomized trials to confirm safety and efficacy.
Observational (n=65)
Yes
Kruchina et al. (2020) conducted an observational in Arrhythmias (n=65). Propafenone was evaluated on Treatment efficacy (cessation of tachycardia attacks or restoration of sinus rhythm). Propafenone was effective in 60% of newborns and young children with supraventricular and ventricular arrhythmias, with adverse and arrhythmogenic effects observed in 6% of patients.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: